Cancer reports最新文献

{"title":"Immune Checkpoint Inhibitor-Related Dysautonomia in Merkel Cell Carcinoma: A Case Report","authors":"Nidhi Kuchimanchi,&nbsp;Sai Gajula,&nbsp;Elizabeth M. Gaughan,&nbsp;Russell G. Witt","doi":"10.1002/cnr2.70274","DOIUrl":"https://doi.org/10.1002/cnr2.70274","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitory pathways that cancer cells exploit to suppress T-cell activation. Although immune-related adverse events (irAEs) linked to ICI therapy are well documented and encompass dermatologic, endocrine, gastrointestinal, hepatic, and neurologic systems, ICI-related dysautonomia remains a rare phenomenon. Management of ICI-related dysautonomia is undefined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We report the case of a 57-year-old male patient treated with neoadjuvant nivolumab for Merkel cell carcinoma who developed ICI-related dysautonomia. His dysautonomia was characterized by orthostatic hypotension, urinary retention, hearing loss, and binocular diplopia in addition to the development of ICI-related hepatitis. We describe the patient's course, including the treatment and outcome of his dysautonomia, and review the literature on this rare toxicity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Due to the mechanism of action of ICIs, irAEs can present with a wide range of manifestations. In this case, prompt recognition of ICI-induced dysautonomia and timely administration of intravenous immunoglobulin (IVIG) led to significant clinical improvement. ICI-induced dysautonomia is a rare condition that is difficult to diagnose and manage.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70274","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report","authors":"Yugo Matsumura,&nbsp;Seiya Ichihara,&nbsp;Kaori Nii,&nbsp;Kazumasa Nanjo,&nbsp;Naoki Kadota,&nbsp;Yoshio Okano,&nbsp;Hisanori Machida,&nbsp;Nobuo Hatakeyama,&nbsp;Hiroyuki Hino,&nbsp;Keishi Naruse,&nbsp;Tsutomu Shinohara,&nbsp;Shoji Sakiyama,&nbsp;Eiji Tacheuchi","doi":"10.1002/cnr2.70273","DOIUrl":"https://doi.org/10.1002/cnr2.70273","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Epidermal growth factor receptor (<i>EGFR</i>) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for <i>EGF</i>R-mutated squamous cell lung carcinoma. We herein present a case of <i>EGFR</i>-mutated squamous cell lung carcinoma that responded to osimertinib.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A mass was observed in the left lower lobe on chest CT. Squamous cell lung carcinoma, cT4N1M1b (adrenal metastasis) stage IVA, was diagnosed based on the findings of a CT-guided percutaneous lung biopsy and a CT scan revealing right adrenal metastasis. The primary tumor was subjected to a genomic analysis with the AmoyDx Pan Lung Cancer PCR panel, which revealed an <i>EGFR</i> mutation (exon 21 L858R). The PD-L1 tumor proportion score was 95%. Osimertinib was initiated as first-line targeted therapy. Tumor shrinkage was observed and maintained over 9 months of treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We encountered a rare <i>EGFR</i>-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with <i>EGFR</i>-mutated squamous cell lung carcinoma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Radiation Oncology in the Era of COVID-19: A Single Institution Analysis","authors":"Melisa Pasli,&nbsp;Michael C. Larkins,&nbsp;George Edwards,&nbsp;Megan Goins,&nbsp;Dayana Gonzalez,&nbsp;Cathleen Cook,&nbsp;Andrew W. Ju,&nbsp;Aidan Burke","doi":"10.1002/cnr2.70277","DOIUrl":"https://doi.org/10.1002/cnr2.70277","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>As a result of the COVID-19 pandemic, health inequities have garnered heightened attention in the public consciousness. In particular, rural access to diagnosis and radiotherapy (RT) for pediatric oncology patients was markedly affected during this period. The fractionated nature of RT creates a transportation burden for this population. We reviewed our institutional experience with pediatric oncologic therapy at a tertiary academic center serving a primarily rural population over a large geographic area.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Pediatric patients aged ≤ 18 years diagnosed with cancer between 2018 and 2022 at our institution were investigated, and we identified the subset of patients who received RT at our institution. Patients were categorized as pre-COVID onset (diagnosed between 2018 and January 31, 2020) or post-COVID onset (diagnosed on or after January 31, 2020, to December 1st, 2022). Chi-Square and Student's t-tests were used to elucidate associations between patient demographics and treatment modalities in the pre- and post-COVID onset groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 114 patients were identified. For patients that received RT (<i>n</i> = 22), 4.5 times more patients traveled from rural counties post-COVID onset (<i>p</i> = 0.027). These patients also saw increased rates of central nervous system (CNS) and non-hematologic cancer diagnosis (<i>p</i> = 0.013 and 0.049, respectively). No difference was seen concerning race, patient age, or average distance traveled (<i>p</i> = 0.371, 0.249, and 0.420, respectively). No difference was seen in the estimated transportation cost incurred as a result of RT treatment (<i>p</i> = 0.144) or in treatment with concurrent chemotherapy (<i>p</i> = 0.245). For the entire cohort, no associations were seen concerning age, race, rural versus urban home county, cancer primary site, or in the prevalence of hematologic- or CNS-based cancers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results highlight the importance of understanding barriers to care to improve outcomes in rural pediatric patients, as the burden of RT may be greater for these patients than for those living in urban counties. Further investigation into barriers to treatment among rural pediatric patients undergoing RT is warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70277","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Expression of lncRNAs EVADR and LUESCC in Colorectal Tumor Tissues and Their Association With the CRC Risk","authors":"Mozhgan Ahmadzadeh,&nbsp;Kamal Shahamiri,&nbsp;Mohammad Raeisi,&nbsp;Negar Jafari,&nbsp;Shaghayegh Kamian,&nbsp;Mahsa Ejlalidiz,&nbsp;Niloufar Sadat Kalaki","doi":"10.1002/cnr2.70232","DOIUrl":"https://doi.org/10.1002/cnr2.70232","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Colorectal cancer (CRC) is a prevalent form of cancer globally and ranks as the second most common cause of cancer-related deaths. Long non-coding RNAs (lncRNAs) are regulatory RNAs that influence gene expression. EVADR and LUESCC are two novel lncRNAs specifically expressed in tumors of glandular origin, such as the colon.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to investigate the expression of EVADR and LUESCC in colorectal tumor tissues and evaluate their potential as diagnostic and prognostic biomarkers in CRC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty cases of colorectal tumor tissues, formalin-fixed, paraffin-embedded (FFPE) from individuals with sporadic CRC, referred from the Pathology Department of Imam Hossein Hospital in Tehran, Iran, were analyzed. The expression patterns of LUESCC and EVADR lncRNAs in CRC patients were examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study reveals upregulation of LUESCC and EVADR lncRNAs in colorectal cancer (CRC) patients compared to normal tissues, with fold changes of 3.52 (<i>p</i> &lt; 0.001) for LUESCC and 3.08 (<i>p</i> &lt; 0.001) for EVADR. ROC curve analysis indicates an area under the curve (AUC) of 0.75 for LUESCC and 0.86 for EVADR, suggesting strong diagnostic potential. Additionally, differential expression analysis shows correlations between lncRNA levels and tumor differentiation grades.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study highlights the potential of LUESCC and EVADR lncRNAs as biomarkers for CRC diagnosis and prognosis. However, limitations include a small sample size that may affect the generalizability of the findings and a lack of functional assays to elucidate their roles in tumor biology. Further research is needed to validate these findings and explore the underlying mechanisms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70232","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetyl Salicylic Acid, COX-2 Inhibitors and Other NSAIDs and Breast Cancer Survival in a Finnish Population-Based Cohort","authors":"M. Malin,&nbsp;M. Murto,&nbsp;O. Arponen,&nbsp;A. Jukkola,&nbsp;A. Siltari,&nbsp;M. Artama,&nbsp;K. Visvanathan,&nbsp;T. Murtola","doi":"10.1002/cnr2.70271","DOIUrl":"https://doi.org/10.1002/cnr2.70271","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Non-steroidal anti-inflammatory drugs (NSAIDs), particularly acetylsalicylic acid (ASA), have been associated with reduced breast cancer (BCa) mortality. While overexpression of cyclooxygenase-2 (COX-2) correlates with poorer prognosis in BCa, COX-2 inhibitors (coxibs) have not demonstrated a survival advantage. However, the evidence remains conflicting and limited. We examined associations between BCa mortality and NSAID use in a Finnish population-based cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study cohort, 73 170 women with new BCa diagnosis during 1995–2013 was identified from The Finnish Cancer Registry. Follow-up data including date and the cause of death, NSAID purchases from 1995 to 2015, mammography screening participation and tumor hormone receptor status, were obtained from national registries. NSAID purchases were categorized into NSAIDs overall, ASA, and coxibs. BCa-specific and overall survival by NSAID use were analyzed using Cox proportional hazard regression, adjusted for age, tumor extent, primary treatment, Charlson comorbidity index, hypertension, diabetes, mammography participation, and hormonal therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Pre-diagnostic use of NSAIDs (HR 0.78, 95% CI: 0.75–0.81) and coxibs (HR 0.76, 95% CI: 0.71–0.81) was associated with reduced BCa mortality, while ASA showed no association. Post-diagnostic NSAID use was associated with increased BCa mortality (HR 1.27, 95% CI: 1.22–1.33), while ASA use (HR 0.84, 95% CI: 0.73–0.97) showed dose-dependent risk reduction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Post-diagnostic use of ASA is associated with reduced BCa-specific mortality, distinguishing ASA from other NSAIDs. Clinical trials are required to determine the ideal ASA dose, frequency, and duration for treating BCa. Pre-diagnostic use of NSAIDs overall is associated with a slight reduction in BCa mortality without dose dependence. The potential role of pre-diagnostic NSAID use as a prognostic factor in BCa warrants further investigation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70271","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144558245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Hormone Receptor-Dependent Correlations Between Angiopoietins and VEGF-C in Primary Breast Cancer: Insights Into Lymphangiogenic Biomarkers”","authors":"","doi":"10.1002/cnr2.70252","DOIUrl":"https://doi.org/10.1002/cnr2.70252","url":null,"abstract":"<p>\u0000 <span>V. Montazeri</span>, <span>P. Varshosaz</span>, <span>A. Fakhrjou</span>, and <span>S. Pirouzpanah</span>, “ <span>Hormone Receptor-Dependent Correlations Between Angiopoietins and VEGF-C in Primary Breast Cancer: Insights Into Lymphangiogenic Biomarkers</span>,” <i>Cancer Reports</i> <span>8</span>, no. <span>5</span> (<span>2025</span>): e70101, https://doi.org/10.1002/cnr2.70101.\u0000 </p><p>These changes can be seen in the published version.</p><p>The publisher apologizes for these errors.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144524704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"M1 Macrophage-Derived Extracellular Particles Induce Cell Death in MDA-MB-231 Cells","authors":"Parth Desai,&nbsp;Anjali Kumari,&nbsp;Saqer Al Abdullah,&nbsp;Azreen Anwar,&nbsp;Kyle Nowlin,&nbsp;Kristen Dellinger","doi":"10.1002/cnr2.70237","DOIUrl":"https://doi.org/10.1002/cnr2.70237","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Triple-negative breast cancer (TNBC), a leading cause of female mortality worldwide, presents a treatment challenge due to the lack of targeted receptors. Macrophages, recognized for their role in the immune response, provide a promising avenue for cancer research. Given that macrophages secrete extracellular particles (EPs), which have been implicated in biological processes, including intercellular communication and immune modulation, it is hypothesized that EPs derived from macrophages could have potential anticancer effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study examines the effect of M1 macrophage-secreted EPs on TNBC cells to investigate their potential as a therapeutic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Polarization was induced in RAW 264.7 macrophages and characterized using ELISA, nitrite release, and microscopy. Macrophage-derived EPs were isolated and characterized using nanoparticle tracking analysis, electron microscopy, and western blotting. The influence of EPs on MDA-MB-231 cells, a TNBC model, was assessed using confocal microscopy. Results showed the increasing expression of caspase 3/7 in a time-dependent manner (0, 24, and 48 h). Cell death was observed in TNBC cells with M1 macrophage-derived EPs, while cell proliferation was observed when M2 macrophage-derived EPs interacted with MDA-MB-231 cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall, results showed that EPs derived from M1 macrophages could induce cell death in MDA-MB-321 cells, opening up potential options for new treatments in TNBC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144524703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: A Retrospective Cohort Study","authors":"Ting-Kai Liao,&nbsp;Ying Jui Chao,&nbsp;Wei-Hsun Lu,&nbsp;Ping-Jui Su,&nbsp;Chih-Jung Wang,&nbsp;Yan-Shen Shan","doi":"10.1002/cnr2.70267","DOIUrl":"https://doi.org/10.1002/cnr2.70267","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to analyze the risk factors for local recurrence (LR) following pancreaticoduodenectomy (PD) in pancreatic cancer patients and to identify vascular features associated with this outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pancreatic cancer frequently involves the mesenteric root, particularly the Porto-mesenteric vein (PV-SMV), impacting survival post curative surgery. However, the relationship between vascular structural changes and LR post-operation remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective data collection was conducted at a single tertiary center from December 2010 to March 2021. Clinical characteristics, surgical-pathological factors, and radiological features were compiled.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 203 pancreatic cancer cases undergoing PD were analyzed, with 72 (35.5%) undergoing concurrent PV-SMV resection (VR). Median overall survival post-operation was 22.4 months. LR occurred in 121 patients (60%) at a median time of 8 months postoperatively. Resectable disease exhibited significantly longer local-recurrence free survival compared to borderline resectable/locally advanced pancreatic cancer (BRPC/LAPC) (median 14.5 vs. 7 months, <i>p</i> &lt; 0.001). The most frequent sites of LR were the mesenteric root (37%), superior mesenteric artery (SMA, 21%), and superior mesenteric vein (SMV, 16%), with similar patterns observed in the VR and non-VR groups. BRPC, LAPC, postoperative CA19-9 above normal range, venous thrombosis, and stenosis were associated with LR (HR: 2.1 [95% CI 1.21–3.68], 2.7 [95% CI 1.6–4.71], 1.8 [95% CI 1.21–2.69], 2.0 [95% CI 1.08–3.92], and 1.6 [95% CI 1.0–2.65], respectively), while PV-SMV resection and enlargement of PV-SMV angle were protective factors (HR: 0.4 [95% CI 0.25–0.67] and 0.3 [95% CI 0.19–0.53]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite aggressive treatment strategies including neoadjuvant therapy and radical surgery, LR in pancreatic cancer remains a challenge. This study highlights potential risk factors, recurrence patterns, and associated vascular features for early identification. These findings may guide clinicians in developing more targeted surveillance strategies and inform future research on preventing LR.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends of Non-Hodgkin Lymphoma Incidence Among Adults in the United States From 2000 to 2020","authors":"Armin Aslani,&nbsp;Morvarid Najafi,&nbsp;Seyed Ehsan Mousavi,&nbsp;Hanieh Marandi,&nbsp;Zahra Yekta,&nbsp;Seyed Aria Nejadghaderi","doi":"10.1002/cnr2.70269","DOIUrl":"https://doi.org/10.1002/cnr2.70269","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Non-Hodgkin lymphoma (NHL) comprises a broad range of hematologic cancers originating from lymphoid tissues. It ranks among the 10 most frequently diagnosed cancers in the United States (US).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aims to analyze trends in the incidence of adult NHL in the US from 2000 to 2020, considering factors such as age, sex, race/ethnicity, and histological subtypes. Additionally, the impact of the COVID-19 pandemic on these incidence trends was explored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Data from the Surveillance, Epidemiology, and End Results program were utilized to examine the age-standardized incidence rates (ASIR) of NHL. Joinpoint regression modeling was applied to calculate the annual percent change (APC) and the average annual percent change (AAPC) of ASIRs over the period from 2000 to 2020. From 2000 to 2019, a total of 962 535 NHL were reported among all ages in the US. They were mostly B-cell NHL (93.59%), in Non-Hispanic Whites (73.31%), and individuals aged 70–79 (25.94%). The overall ASIRs were 55.58 (55.43, 55.73) for men and 36.00 (35.89, 36.11) for women. There was a notable decline in ASIRs following the onset of the COVID-19 pandemic from 2019 to November 2020, with a percentage change of −10.52% (−11.60, −9.45). The overall AAPC for adult NHL was 0.45% (0.33, 0.62) in men and 0.38% (0.21, 0.57) in women, indicating a minimal yet significant increase.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>NHL incidence increased over 2000–2019. These trends in incidence rates exhibited variation across different races, sexes, age groups, and histological subtypes. COVID-19 led to a decrease in NHL incidence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70269","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward the Patient Participation Pathway: A Mixed Methods Study of Patients With Cancer and Other Chronic Diseases","authors":"Paloma Casado Durández,&nbsp;Eleuterio A. Sánchez-Romero,&nbsp;Alicia Negrón Fraga,&nbsp;Concepción Rey Benayas,&nbsp;Claudia Ruiz-Huerta García de Viedma,&nbsp;Davinia Medina Ferrer,&nbsp;Ildefonso González Solana,&nbsp;Maria Caballero Nahúm,&nbsp;Mercedes Vinuesa Sebastián,&nbsp;Rosa María de la Salazar Guerra,&nbsp;Nina Cadeau-Comte,&nbsp;Laura Jiménez-Ortega,&nbsp;Juan Nicolás Cuenca-Zaldívar","doi":"10.1002/cnr2.70258","DOIUrl":"https://doi.org/10.1002/cnr2.70258","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Chronic diseases such as breast cancer, colon cancer, chronic obstructive pulmonary disease (COPD), stroke, diabetes, depression, and myocardial infarction remain leading causes of death worldwide, contributing significantly to premature mortality. Understanding psychosocial impact is essential for comprehensive care. This study aimed to explore how patients with different chronic disease profiles experience participation during the chronic phase, using a mixed-methods approach.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A convergent parallel mixed-methods design was used to integrate qualitative data from focus group discussions and quantitative data from physical performance tests. A total of 117 patients were recruited through clinical referrals and patient associations, using purposive and snowball sampling. Thematic analysis was performed collaboratively to ensure consistency. Statistical analysis (R v4.1.3) examined the coding and sentiment differences across disease profiles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The sample included 117 patients (mean age = 58.66 years; majority were female). Significant differences in qualitative coding were found between pathologies (<i>p</i> &lt; 0.001), particularly regarding quality of life and emotional experience in COPD and stroke patients compared to others (<i>p</i> &lt; 0.05). Topic modeling identified seven relevant topics, and two main coding clusters emerged: one focused on pain and basic activities, and the other on environment and advanced activities. Positive emotions were predominant (<i>p</i> &lt; 0.001). The thematic analysis revealed three main themes: quality of life, emotional experience, and empowerment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with different chronic conditions experienced disease and unique participation. Patients with breast cancer prioritized pain and daily function, while patients with COPD focused on autonomy in self-management. These findings support the need for individualized disease-specific approaches to promote meaningful patient participation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70258","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}